CytomX Therapeutics, Inc.
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

Abstract:

The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.